•   
  •   
  •   

US FDA approves 1st long-acting HIV drug combo, monthly shots

12:15  23 january  2021
12:15  23 january  2021 Source:   nbcnews.com

Trump brought leadership turmoil to security agencies in run-up to Capitol riot

  Trump brought leadership turmoil to security agencies in run-up to Capitol riot The Department of Justice, Department of Defense and the Department of Homeland Security all have ‘acting’ secretaries at a crisis moment for the nation. The leadership vacuum is the product of President Trump’s tempestuous relationships with his Cabinet secretaries and tendency to replace them for long periods of time with acting officials who lack Senate confirmation — a pattern that has led to turmoil atop critical federal agencies for much of his presidency.

U.S. regulators have approved the first long - acting drug combo for HIV , monthly shots that can replace the daily pills people use to control infection of the AIDS virus . Thursday's approval of the two- shot combo called Cabenuva is expected to make it easier for people to stay on track with their

U.S. regulators have approved the first long - acting drug combo for HIV , monthly shots that can replace the daily pills now used to control The agency also approved a pill version of cabotegravir to be taken with rilpivarine for a month before switching to the shots to be sure the drugs are well

U.S. regulators have approved the first long-acting drug combo for HIV, monthly shots that can replace the daily pills now used to control infection with the AIDS virus.

Thursday’s approval of the two-shot combo called Cabenuva is expected to make it easier for people to stay on track with their HIV medicines and to do so with more privacy. It’s a huge change from not long ago, when patients had to take multiple pills several times a day, carefully timed around meals.

a close up of a bottle: Vials of the HIV treatment Cabenuva. (ViiV Healthcare via AP) © Provided by NBC News Vials of the HIV treatment Cabenuva. (ViiV Healthcare via AP)

“That will enhance quality of life” to need treatment just once a month, said Dr. Steven Deeks, an HIV specialist at the University of California, San Francisco, who has no ties to the drug’s makers. “People don’t want those daily reminders that they’re HIV infected.”

Timeline: Wuhan, one year after coronavirus lockdown

  Timeline: Wuhan, one year after coronavirus lockdown Timeline: Wuhan, one year after coronavirus lockdownFollowing is a timeline of key events since the first cases of the virus were detected in the city of 11 million residents in Hubei province.

U.S. regulators have approved the first long - acting drug combo for HIV , monthly shots that can replace the daily pills now used to control infection with the AIDS virus . Thursday’s approval of the two- shot combo called Cabenuva is expected to make it easier for people to stay on track with their

U.S. regulators have approved the first long - acting combo drug for HIV , monthly shots that can replace the daily pills that have been used for decades Thursday’s approval of the two- shot combo called Cabenuva is expected to make it easier for people to stay on track with their HIV medicines and

Cabenuva combines rilpivirine, sold as Edurant by Johnson & Johnson’s Janssen unit, and a new drug — cabotegravir, from ViiV Healthcare. They’re packaged together and given as separate shots once a month. Dosing every two months also is being tested.

The U.S. Food and Drug Administration approved Cabenuva for use in adults who have had their disease well controlled by conventional HIV medicines and who have not shown signs of viral resistance to the two drugs in Cabenuva.

The agency also approved a pill version of cabotegravir to be taken with rilpivarine for a month before switching to the shots to be sure the drugs are well tolerated.


Video: Lilly antibody drug 80% effective at preventing Covid-19, according to nursing home study (CNBC)

Full list of Trump's last-minute pardons and commuted sentences

  Full list of Trump's last-minute pardons and commuted sentences The list, made public early Wednesday morning, included his former chief strategist and longtime ally Steve Bannon.The list, made public early Wednesday morning, included his former chief strategist and longtime ally Steve Bannon as well as his former top fundraiser Elliott Broidy.

U.S. regulators have approved the first long - acting drug combo for HIV , monthly shots that can replace the daily pills now used to control The agency also approved a pill version of cabotegravir to be taken with rilpivarine for a month before switching to the shots to be sure the drugs are well

U.S. regulators have approved the first long - acting drug combo for HIV , monthly shots that can replace daily pills. Thursday’s approval of the two- shot combo called Cabenuva is expected to make it easier for people to stay on track with their HIV medicines and to do so with more privacy.

ViiV said the shot combo would cost $5,940 for an initial, higher dose and $3,960 per month afterward. The company said that is “within the range” of what one-a-day pill combos cost now. How much a patient pays depends on insurance, income and other things.

Studies found that patients greatly preferred the shots.

“Even people who are taking one pill once a day just reported improvement in their quality of life to switch to an injection,” said Dr. Judith Currier, an HIV specialist at the University of California, Los Angeles. She consults for ViiV and wrote a commentary accompanying one study of the drug in the New England Journal of Medicine.

Deeks said long-acting shots also give hope of reaching groups that have a hard time sticking to treatment, including people with mental illness or substance abuse problems.

“There’s a great unmet need” that the shots may fill, he said.

Separately, ViiV plans to seek approval for cabotegravir for HIV prevention. Two recent studies found that cabotegravir shots every two months were better than daily Truvada pills for keeping uninfected people from catching the virus from an infected sex partner.

Follow NBC Out on Twitter, Facebook & Instagram

Progressives Renew Push for $2,000 Monthly Stimulus Checks but Economists Are Skeptical .
"I don't necessarily know that providing $2,000 on a monthly basis would necessarily be the right approach at this stage," the chief U.S. economist at Oxford Economics told Newsweek.More than 50 House Democrats, led by Representative Ilhan Omar of Minnesota, sent a letter to President Joe Biden and Vice President Kamala Harris on Thursday urging their administration to back recurring direct cash payments.

usr: 0
This is interesting!